Chemomab Therapeutics (CMMB) to Release Earnings on Thursday

Chemomab Therapeutics (NASDAQ:CMMB) is anticipated to issue its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter.

Chemomab Therapeutics Stock Up 5.2 %

Shares of Chemomab Therapeutics stock opened at $1.63 on Thursday. The business has a 50 day moving average of $1.97 and a 200 day moving average of $1.73. Chemomab Therapeutics has a 52 week low of $0.58 and a 52 week high of $2.55. The company has a market cap of $23.41 million, a PE ratio of -1.63 and a beta of 0.66.

Analysts Set New Price Targets

Several brokerages have commented on CMMB. Maxim Group upped their price objective on shares of Chemomab Therapeutics from $4.00 to $7.00 and gave the stock a “buy” rating in a report on Thursday, February 20th. Oppenheimer reiterated an “outperform” rating and set a $11.00 price target (down previously from $13.00) on shares of Chemomab Therapeutics in a research report on Friday, November 15th.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).